CN120661638A - 聚乙二醇化的破伤风神经毒素和张力减退的治疗 - Google Patents
聚乙二醇化的破伤风神经毒素和张力减退的治疗Info
- Publication number
- CN120661638A CN120661638A CN202510841942.0A CN202510841942A CN120661638A CN 120661638 A CN120661638 A CN 120661638A CN 202510841942 A CN202510841942 A CN 202510841942A CN 120661638 A CN120661638 A CN 120661638A
- Authority
- CN
- China
- Prior art keywords
- tent
- peg
- pegylated
- seq
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24068—Tentoxilysin (3.4.24.68), i.e. tetanus neurotoxin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Pulmonology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Detergent Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2018902779 | 2018-07-31 | ||
| AU2018902779A AU2018902779A0 (en) | 2018-07-31 | Composition and method | |
| CN201980057158.3A CN112638937B (zh) | 2018-07-31 | 2019-07-30 | 聚乙二醇化的破伤风神经毒素和张力减退的治疗 |
| PCT/AU2019/050793 WO2020024002A1 (en) | 2018-07-31 | 2019-07-30 | Pegylated tetanus neurotoxins and treatment of hypotonia |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980057158.3A Division CN112638937B (zh) | 2018-07-31 | 2019-07-30 | 聚乙二醇化的破伤风神经毒素和张力减退的治疗 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN120661638A true CN120661638A (zh) | 2025-09-19 |
Family
ID=69230503
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202510841942.0A Pending CN120661638A (zh) | 2018-07-31 | 2019-07-30 | 聚乙二醇化的破伤风神经毒素和张力减退的治疗 |
| CN201980057158.3A Active CN112638937B (zh) | 2018-07-31 | 2019-07-30 | 聚乙二醇化的破伤风神经毒素和张力减退的治疗 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980057158.3A Active CN112638937B (zh) | 2018-07-31 | 2019-07-30 | 聚乙二醇化的破伤风神经毒素和张力减退的治疗 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210353724A1 (https=) |
| EP (2) | EP4134133A1 (https=) |
| JP (3) | JP2021533201A (https=) |
| KR (1) | KR20210040407A (https=) |
| CN (2) | CN120661638A (https=) |
| AU (1) | AU2019315327B2 (https=) |
| BR (1) | BR112021001520A2 (https=) |
| CA (2) | CA3167665A1 (https=) |
| MX (1) | MX2021001181A (https=) |
| NZ (1) | NZ772266A (https=) |
| SG (1) | SG11202100646SA (https=) |
| WO (1) | WO2020024002A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240268895A1 (en) | 2023-02-15 | 2024-08-15 | Canon Medical Systems Corporation | X-ray diagnostic apparatus, x-ray diagnostic system, and x-ray diagnostic method |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003200441B2 (en) * | 1998-04-29 | 2006-07-06 | Allergan, Inc. | Compositions and methods for modulating neural sprouting |
| GB9914861D0 (en) * | 1999-06-25 | 1999-08-25 | Imperial College | Tetanus toxin polypeptides |
| WO2002000172A2 (en) * | 2000-06-28 | 2002-01-03 | Ira Sanders | Methods for using tetanus toxin for benificial purposes in animals (mammals) |
| US20020197278A1 (en) * | 2001-06-21 | 2002-12-26 | Surromed, Inc. | Covalent coupling of botulinum toxin with polyethylene glycol |
| AU2003237346A1 (en) * | 2002-05-31 | 2003-12-19 | Thomas Jefferson University | Compositions and methods for transepithelial molecular transport |
| WO2008024879A1 (en) * | 2006-08-25 | 2008-02-28 | University Of Maryland, Baltimore | Use of tetanus toxin to amplify inadequate voluntary muscle contraction or to improve muscle tone in an animal actively vaccinated against the toxin and a regimen for treatment |
| KR101818777B1 (ko) * | 2009-04-27 | 2018-01-15 | 메르츠 파마 게엠베하 운트 코. 카가아 | 신경독 폴리펩티드의 양 및 이들의 촉매 활성 및 단백질 분해 활성의 결정수단 및 방법 |
| ES2616258T3 (es) * | 2010-03-15 | 2017-06-12 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Péptidos, conjugados y métodos para aumentar la inmunogenicidad de una vacuna |
| US20170151316A1 (en) * | 2014-07-02 | 2017-06-01 | Spherium Biomed, S.L. | Methods of increasing muscle mass using non-toxic tetanus toxin c fragment (ttc) |
| US10704035B2 (en) * | 2015-08-27 | 2020-07-07 | President And Fellows Of Harvard College | Compositions and methods for treatment of pain |
| CN106692963B (zh) * | 2016-12-28 | 2020-12-22 | 中国人民解放军军事医学科学院生物工程研究所 | 一种用于预防金黄色葡萄球菌感染和破伤风的联合疫苗 |
| EP3723784A4 (en) * | 2017-12-15 | 2022-01-12 | The Medical College of Wisconsin, Inc. | USE OF MODIFIED CLOSTRIDIAL NEUROTOXINS AS VACCINES AND CONJUGATE VACCINE PLATFORMS |
| WO2021155427A1 (en) * | 2020-02-03 | 2021-08-12 | Snoretox Pty Ltd | Composition and method |
-
2019
- 2019-07-30 AU AU2019315327A patent/AU2019315327B2/en active Active
- 2019-07-30 EP EP22183027.6A patent/EP4134133A1/en active Pending
- 2019-07-30 EP EP19843147.0A patent/EP3830110A4/en active Pending
- 2019-07-30 MX MX2021001181A patent/MX2021001181A/es unknown
- 2019-07-30 SG SG11202100646SA patent/SG11202100646SA/en unknown
- 2019-07-30 KR KR1020217006098A patent/KR20210040407A/ko not_active Ceased
- 2019-07-30 JP JP2021529491A patent/JP2021533201A/ja active Pending
- 2019-07-30 BR BR112021001520-5A patent/BR112021001520A2/pt unknown
- 2019-07-30 CA CA3167665A patent/CA3167665A1/en active Pending
- 2019-07-30 NZ NZ772266A patent/NZ772266A/en unknown
- 2019-07-30 CA CA3108079A patent/CA3108079C/en active Active
- 2019-07-30 CN CN202510841942.0A patent/CN120661638A/zh active Pending
- 2019-07-30 US US17/261,975 patent/US20210353724A1/en active Pending
- 2019-07-30 CN CN201980057158.3A patent/CN112638937B/zh active Active
- 2019-07-30 WO PCT/AU2019/050793 patent/WO2020024002A1/en not_active Ceased
-
2023
- 2023-11-20 JP JP2023196375A patent/JP7786745B2/ja active Active
-
2025
- 2025-11-25 JP JP2025203043A patent/JP2026026159A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3108079C (en) | 2023-10-10 |
| EP3830110A1 (en) | 2021-06-09 |
| AU2019315327B2 (en) | 2024-05-09 |
| NZ772266A (en) | 2022-09-30 |
| JP2021533201A (ja) | 2021-12-02 |
| CA3108079A1 (en) | 2020-02-06 |
| US20210353724A1 (en) | 2021-11-18 |
| JP2024014975A (ja) | 2024-02-01 |
| WO2020024002A1 (en) | 2020-02-06 |
| KR20210040407A (ko) | 2021-04-13 |
| SG11202100646SA (en) | 2021-02-25 |
| MX2021001181A (es) | 2021-04-19 |
| NZ789962A (en) | 2025-07-25 |
| BR112021001520A2 (pt) | 2021-04-20 |
| CN112638937B (zh) | 2025-06-17 |
| EP4134133A1 (en) | 2023-02-15 |
| JP7786745B2 (ja) | 2025-12-16 |
| EP3830110A4 (en) | 2022-03-02 |
| AU2019315327A1 (en) | 2021-02-11 |
| CN112638937A (zh) | 2021-04-09 |
| JP2026026159A (ja) | 2026-02-16 |
| CA3167665A1 (en) | 2020-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11617780B2 (en) | Antigenic Epstein Barr virus polypeptides | |
| KR100594787B1 (ko) | 경구용 백신 및 치료제의 전신 전달용 조성물 및 방법 | |
| Feldman et al. | Epidermal growth factor stimulates ornithine decarboxylase activity in the digestive tract of mouse | |
| Tendler et al. | A Schistosoma mansoni fatty acid-binding protein, Sm14, is the potential basis of a dual-purpose anti-helminth vaccine. | |
| DE69331901T2 (de) | Impfstoff auf urease-basis gegen helicobacter infektionen | |
| US11993636B2 (en) | Antigenic OspA polypeptides | |
| WO2007113633A2 (en) | Immunogenic compositions comprising cat allergen fel dl | |
| JP2026026159A (ja) | Ｐｅｇ化破傷風神経毒素および筋緊張低下の治療 | |
| AU2026201375A1 (en) | Treatment of urticaria | |
| AU2010241253B2 (en) | Synthetic active peptide fragments | |
| Fettelschoss et al. | Interleukin 31 and targeted vaccination in a case series of six horses with chronic pruritus | |
| US20230057367A1 (en) | Composition and method | |
| CN108904791A (zh) | 一种产气荚膜梭菌α毒素重组亚单位疫苗及其生产方法 | |
| CN118931931A (zh) | 一种产气荚膜梭菌epsilon毒素-铁蛋白纳米颗粒抗原的制备方法 | |
| Yu et al. | Development and evaluation of candidate vaccine and antitoxin against botulinum neurotoxin serotype F | |
| CN119552230A (zh) | 一种脂肪酸化修饰的白喉毒素抗原及其应用 | |
| CN117177774A (zh) | Sars-cov-2受体结合结构域与载体蛋白的共价缀合物以及包含它们的疫苗组合物 | |
| CN121532207A (zh) | 用于治疗特应性皮炎的主动免疫 | |
| Atassi | Perspectives of the immunology of proteins | |
| EA048316B1 (ru) | Ковалентные конъюгаты рецептор-связывающего домена sars-cov-2 и белка-носителя и содержащие их вакцинные композиции | |
| HK40025696A (en) | Peptide immunogens of il-31 and formulations thereof for the treatment and/or prevention of atopic dermatitis | |
| MYCOPLASMA | PARAGALLINARUM VACCINE | |
| NZ715570B2 (en) | Cationic neurotoxins | |
| CZ20001399A3 (cs) | Prostředky a způsoby pro systémové podání orálních vakcín a terapeutických činidel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |